- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04966858
Individualisierte Studie zur Rückfütterung zur Optimierung der Zuwächse bei Patienten (i-STRONG)
Erneuerung der multizentrischen randomisierten kontrollierten Studie zur Refeeding bei Anorexia Nervosa
The primary purpose of the trial is to compare the efficacy and safety of Individualized Caloric Refeeding (ICR) to the new standard of care, Higher Calorie Refeeding (HCR), in hospitalized patients with atypical anorexia nervosa (AAN), and clinical remission over one year of follow-up.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Atypical Anorexia Nervosa (AAN) is a new diagnosis describing patients with malnutrition and significant weight loss yet "normal" weight. These patients responded poorly to HCR, the superior refeeding treatment in the parent trial, which was designed for low-weight patients with typical AN. The proposed trial will examine the safety and efficacy of a new treatment for AAN with the potential to improve treatment outcomes for this diverse and growing patient population. The major finding motivating the proposed trial is that participants with AAN gained weight 40 percent slower and required 3.0 additional days in hospital to restore medical stability on HCR, as compared to AN. The research team has developed Individualized Caloric Refeeding (ICR), which doses calories to weight consistent with other pediatric treatments (e.g. medication).
The primary purpose of the proposed trial is to compare the efficacy and safety of ICR to the new standard of care (HCR) in hospitalized patients with AAN. The investigators hypothesize that ICR will restore medical stability faster than HCR with no increase in electrolyte abnormalities. After hospitalization, the major barrier to care in AAN is lack of consensus on clinical remission and whether these formerly overweight patients should gain weight to recover. The research team will examine metabolic, hormonal and psychological markers during long-term follow-up, toward the goal of developing a definition of clinical remission in AAN.
Design Summary: Randomized controlled trial in N=74 participants age 12-24 with AAN, consented upon hospital admission, randomly assigned to ICR or HCR, followed daily in hospital and at 3, 6, 9 and 12 mo.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
California
-
Palo Alto, California, Vereinigte Staaten, 94304
- Stanford University Lucille Packard Children's Hospital
-
San Francisco, California, Vereinigte Staaten, 94158
- University of California, San Francisco Benioff Children's Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Age 12-24 yrs
-
Meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for AAN
-
Hospitalized with medical instability, as defined by:
- night time heart rate (HR) <45 bpm,
- systolic blood pressure (SBP) <90 mmHg,
- temperature <35.6° C,
- orthostatic Δ HR >35 bpm, or
- orthostatic Δ SBP >20 mmHg
Exclusion Criteria:
- Bulimia nervosa
- Current pregnancy
- Chronic disease (e.g. immune, renal disease)
- Acute/active suicidality or psychosis
- Hospital admissions for refeeding in the prior 6 mo.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Individualized Caloric Refeeding (ICR)
Starting 50 kcal/kg/d, increasing by 200 kcal/d to goal |
Meal-based refeeding in hospital, starting at 50 calories per kilogram of body weight, and increasing by 200 calories per day until caloric goal achieved
Andere Namen:
|
|
Aktiver Komparator: Higher Calorie Refeeding (HCR)
Starting 2000 kcal/d, increasing by 200 kcal/d to goal |
Meal-based refeeding in hospital, starting at 2000 calories per day, and increasing by 200 calories per day until caloric goal achieved
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time to Achieve Medical Stability in Hospital
Zeitfenster: Inpatient hospitalization from day of admission to day of discharge, average 1-2 weeks
|
Medical stability will be adjudicated by a five-point index: (1) 24 hour heart rate of 45 beats/min or more, (2) systolic blood pressure of 90 millimeters of mercury (mmHg) or more, (3) temperature of 35.6° C or more, (4) orthostatic increase in heart rate of 35 beats/min or less, (5) orthostatic change in systolic blood pressure of 20 mmHg or less. |
Inpatient hospitalization from day of admission to day of discharge, average 1-2 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of Low Serum Electrolytes During Refeeding in Hospital
Zeitfenster: Inpatient hospitalization from day of admission to day of discharge, average 1-2 weeks
|
Incidence of low electrolytes will be defined as: (1) hypophosphatemia less than 3 milligrams per deciliter (mg/dL), (2) hypomagnesaemia less than 1.8 mg/dL, and (3) hypokalemia less than 3.5 milliequivalent per liter (mEq/L) during hospitalization. |
Inpatient hospitalization from day of admission to day of discharge, average 1-2 weeks
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage Median BMI (mBMI) Over 12 Months
Zeitfenster: 12 months post-study hospitalization
|
Measured BMI will be divided by the mBMI for age and sex per national growth data to give the percentage mBMI. |
12 months post-study hospitalization
|
|
Eating Disorder Examination Questionnaire (EDE-Q) Score Over 12 Months
Zeitfenster: 12 months post-study hospitalization
|
The EDE-Q will be self-administered; scores range from 0 to 6, with higher scores indicating greater severity and a worse outcome. |
12 months post-study hospitalization
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Andrea K Garber, PhD, RD, University of California, San Francisco
- Hauptermittler: Neville H Golden, MD, Stanford University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2R01HD082166-06A1 (US NIH Stipendium/Vertrag)
- 20-32551 (Andere Kennung: UCSF IRB)
- R01HD082166 (US NIH Stipendium/Vertrag)
- HD082166 (Andere Kennung: Federal Identifier, per NIH application)
- P0547076 (Andere Kennung: NIH Application Identifier)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .